Heartware International (HTWR) 88.18 $HTWR
HeartWare Schedules Fourth Quarter Conference Call And Webcast
PR Newswire - Fri Feb 13, 10:00AM CST
HeartWare International, Inc. (NASDAQ:HTWR) has scheduled a conference call to discuss its financial results for the three months ended December 31, 2014, at 8:00 a.m. U.S. Eastern Daylight Time on Thursday, February 26, 2015. The Company plans to release the financial results prior to the conference call.
HTWR: 88.18 (-0.09)
Shares of HTWR Up 15.4% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Feb 13, 9:55AM CST
SmarTrend identified an Uptrend for HeartWare International (NASDAQ:HTWR) on January 6th, 2015 at $76.40. In approximately 1 month, HeartWare International has returned 15.40% as of today's recent price of $88.16.
HTWR: 88.18 (-0.09)
Thoratec Arrests Decline In LVAD Sales In 4th Quarter 2014, Revive-IT Is 'Dead'
Robert Honeywill - Seeking Alpha - Fri Feb 13, 8:36AM CST
This article is a continuation of my series of articles developing an investment strategy based on an area of unmet need in the health sector, viz ., long-term therapies for late stage heart failure. The significant players are Thoratec (NASDAQ:...
SSH: 5.26 (-0.02), THOR: 40.01 (+0.54), HTWR: 88.18 (-0.09)
HeartWare International Has Returned 13.7% Since SmarTrend Recommendation (HTWR)
Comtex SmarTrend(R) - Fri Feb 06, 9:34AM CST
SmarTrend identified an Uptrend for HeartWare International (NASDAQ:HTWR) on January 6th, 2015 at $76.40. In approximately 1 month, HeartWare International has returned 13.71% as of today's recent price of $86.87.
HTWR: 88.18 (-0.09)
HeartWare Presentation At The 2015 Leerink Global Healthcare Conference To Be Webcast
PR Newswire - Thu Feb 05, 8:10AM CST
HeartWare International, Inc. (NASDAQ:HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the 2015 Leerink Global Healthcare Conference at 10:20 a.m. EST on Thursday, February 12, 2015. The conference is being held February 11-12 at the Waldorf Astoria in New York City.
HTWR: 88.18 (-0.09)
If Thoratec's Woes Are Heartware's Gain, That's Disastrous For Both
Robert Honeywill - Seeking Alpha - Wed Feb 04, 8:41AM CST
An area of potential above average real growth This article is a continuation of my series looking at corporations with mechanical heart assist devices as part of a strategy for seeking above average returns by investing in heart health related...
SSH: 5.26 (-0.02), THOR: 40.01 (+0.54), HTWR: 88.18 (-0.09)
Clinical Hold For Revive-IT Trial Raises Questions About Thoratec And Heartware
Robert Honeywill - Seeking Alpha - Wed Feb 04, 8:41AM CST
From the Revive-IT official web-site : REVIVE-IT is a two-part study consisting of a trial and a registry. The purpose of the REVIVE-IT study is to find out whether people with advanced heart failure who are not candidates for a heart transplant...
SSH: 5.26 (-0.02), THOR: 40.01 (+0.54), HTWR: 88.18 (-0.09)
HeartWare: Integral To A Heart Health Related Investment Strategy
Robert Honeywill - Seeking Alpha - Tue Jan 27, 9:53AM CST
An area of potential above average real growth In my article, " Thoratec: At The Heart Of A Health-Related Investment Strategy ", I wrote, Late stage heart failure (NYSE: HF ) is a prime example, with a large and growing population of patients...
SSH: 5.26 (-0.02), THOR: 40.01 (+0.54), HTWR: 88.18 (-0.09)
Heartware International (HTWR) Shares Cross Above 200 DMA
MarketNewsVideo.com - Thu Jan 22, 3:44PM CST
In trading on Thursday, shares of Heartware International Inc crossed above their 200 day moving average of $82.31, changing hands as high as $82.32 per share. Heartware International Inc shares are currently trading up about 0.7% on the day.
HTWR: 88.18 (-0.09)
HeartWare Announces Preliminary Q4, 2014 Revenue Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 14, 4:55PM CST
HeartWare International, Inc. (HTWR) recently announced preliminary top-line results for fourth quarter and full year 2014.
ABMD: 60.39 (+0.46), INGN: 33.53 (+2.32), HTWR: 88.18 (-0.09), SURG: 4.44 (-0.02)
HeartWare International Announces Preliminary Fourth Quarter 2014 Revenues
PR Newswire - Tue Jan 13, 10:05AM CST
HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that it expects revenues for the fourth quarter of 2014 will be approximately $73 million, bringing expected full-year 2014 revenues to approximately $278 million.
HTWR: 88.18 (-0.09)
HeartWare Begins HVAD® LATERAL Study, A Clinical Trial Of Advanced Heart Failure Patients Implanted Via Less-Invasive Thoracotomy Technique
PR Newswire - Tue Jan 13, 7:30AM CST
HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced the first patient implant in the HVAD® LATERAL Study, a U.S. Investigational Device Exemption (IDE) clinical trial in which the HeartWare® Ventricular Assist System, featuring the HVAD® Pump, is implanted through a less-invasive thoracotomy procedure in patients with end-stage heart failure who are awaiting a heart transplant.
HTWR: 88.18 (-0.09)
HeartWare Presentation At The J.P. Morgan 33rd Annual Healthcare Conference To Be Webcast
PR Newswire - Fri Jan 02, 8:15AM CST
HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the J.P. Morgan 33rd Annual Healthcare Conference at 11:00 a.m. EST (8:00 a.m. PST) on Tuesday, January 13, 2015. The conference is being held January 12-15 at The Westin St. Francis in San Francisco, California.
JPM: 59.67 (+0.10), HTWR: 88.18 (-0.09)
Volcano Acquired by Royal Philips for $1.2B: What Wall Street's Saying
at The Street - Wed Dec 17, 2:20PM CST
Volcano Corp. shares surged more than 50% on Wednesday after Royal Philips agreed to acquire the medical technology company for $1.2 billion.
BSX: 14.98 (+0.24), SPNC: 33.69 (-0.06), ABT: 46.09 (+0.87), PHG: 28.93 (-0.07), MDT: 75.26 (+0.33), TRIV: 10.07 (+0.15), VOLC: 17.98 (+0.03), STJ: 67.48 (+0.65), THOR: 40.01 (+0.54), HTWR: 88.18 (-0.09), ELGX: 14.51 (+0.21), ATRC: 18.86 (+0.04), NVDQ: 15.12 (+0.51)
HeartWare Presentation At The Oppenheimer 25th Annual Healthcare Conference To Be Webcast
PR Newswire - Thu Dec 04, 11:35AM CST
HeartWare International, Inc. (NASDAQ:HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Oppenheimer 25th Annual Healthcare Conference at 10:20 a.m. EST on Wednesday, December 10, 2014. The conference is being held December 10-11, 2014 at the Crowne Plaza Hotel in New York City.
HTWR: 88.18 (-0.09)
Thoratec: At The Heart Of A Health-Related Investment Strategy
Robert Honeywill - at Seeking Alpha - Sun Nov 30, 3:48AM CST
About the headline It is my contention, for Western economies, we will enjoy far lower growth in the future than we have enjoyed over the last several decades. For investors, it is not an optimal strategy to adopt a "rising tide lifts all boats"...
SSH: 5.26 (-0.02), THOR: 40.01 (+0.54), HTWR: 88.18 (-0.09)
HeartWare Presentation At The Canaccord Genuity 2014 Medical Technology & Diagnostics Forum To Be Webcast
PR Newswire - Thu Nov 13, 11:11AM CST
HeartWare International, Inc. (NASDAQ:HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Canaccord Genuity 2014 Medical Technology & Diagnostics Forum at 10:00 a.m. EST on Thursday, November 20, 2014. The one-day conference is being held at the Westin Grand Central, New York.
HTWR: 88.18 (-0.09)
Update: Heartware International Q3 2014 Earnings
Andy Batts - at Seeking Alpha - Sat Nov 08, 1:38PM CST
HTWR: 88.18 (-0.09)
HeartWare Presentation At The Credit Suisse 2014 Healthcare Conference To Be Webcast
PR Newswire - Fri Nov 07, 8:00AM CST
HeartWare International, Inc. (NASDAQ:HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Credit Suisse 2014 Healthcare Conference at 2:00 p.m. MST (4:00 pm EST) on Wednesday, November 12, 2014. The conference is being held November 10-13 at the Arizona Biltmore in Phoenix.
HTWR: 88.18 (-0.09)
Heartware International (HTWR) Downgraded From Hold to Sell
at The Street - Mon Nov 03, 8:38AM CST
Heartware International (HTWR) has been downgraded by TheStreet Ratings from Hold to Sell with a ratings score of D+.
HTWR: 88.18 (-0.09)
HeartWare Schedules Fourth Quarter Conference Call And Webcast
PR Newswire - Fri Feb 13, 10:00AM CST
HeartWare International, Inc. (NASDAQ:HTWR) has scheduled a conference call to discuss its financial results for the three months ended December 31, 2014, at 8:00 a.m. U.S. Eastern Daylight Time on Thursday, February 26, 2015. The Company plans to release the financial results prior to the conference call.
HTWR: 88.18 (-0.09)
Shares of HTWR Up 15.4% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Feb 13, 9:55AM CST
SmarTrend identified an Uptrend for HeartWare International (NASDAQ:HTWR) on January 6th, 2015 at $76.40. In approximately 1 month, HeartWare International has returned 15.40% as of today's recent price of $88.16.
HTWR: 88.18 (-0.09)
Thoratec Arrests Decline In LVAD Sales In 4th Quarter 2014, Revive-IT Is 'Dead'
Robert Honeywill - Seeking Alpha - Fri Feb 13, 8:36AM CST
This article is a continuation of my series of articles developing an investment strategy based on an area of unmet need in the health sector, viz ., long-term therapies for late stage heart failure. The significant players are Thoratec (NASDAQ:...
SSH: 5.26 (-0.02), THOR: 40.01 (+0.54), HTWR: 88.18 (-0.09)
HeartWare International Has Returned 13.7% Since SmarTrend Recommendation (HTWR)
Comtex SmarTrend(R) - Fri Feb 06, 9:34AM CST
SmarTrend identified an Uptrend for HeartWare International (NASDAQ:HTWR) on January 6th, 2015 at $76.40. In approximately 1 month, HeartWare International has returned 13.71% as of today's recent price of $86.87.
HTWR: 88.18 (-0.09)
HeartWare Presentation At The 2015 Leerink Global Healthcare Conference To Be Webcast
PR Newswire - Thu Feb 05, 8:10AM CST
HeartWare International, Inc. (NASDAQ:HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the 2015 Leerink Global Healthcare Conference at 10:20 a.m. EST on Thursday, February 12, 2015. The conference is being held February 11-12 at the Waldorf Astoria in New York City.
HTWR: 88.18 (-0.09)
If Thoratec's Woes Are Heartware's Gain, That's Disastrous For Both
Robert Honeywill - Seeking Alpha - Wed Feb 04, 8:41AM CST
An area of potential above average real growth This article is a continuation of my series looking at corporations with mechanical heart assist devices as part of a strategy for seeking above average returns by investing in heart health related...
SSH: 5.26 (-0.02), THOR: 40.01 (+0.54), HTWR: 88.18 (-0.09)
Clinical Hold For Revive-IT Trial Raises Questions About Thoratec And Heartware
Robert Honeywill - Seeking Alpha - Wed Feb 04, 8:41AM CST
From the Revive-IT official web-site : REVIVE-IT is a two-part study consisting of a trial and a registry. The purpose of the REVIVE-IT study is to find out whether people with advanced heart failure who are not candidates for a heart transplant...
SSH: 5.26 (-0.02), THOR: 40.01 (+0.54), HTWR: 88.18 (-0.09)
HeartWare: Integral To A Heart Health Related Investment Strategy
Robert Honeywill - Seeking Alpha - Tue Jan 27, 9:53AM CST
An area of potential above average real growth In my article, " Thoratec: At The Heart Of A Health-Related Investment Strategy ", I wrote, Late stage heart failure (NYSE: HF ) is a prime example, with a large and growing population of patients...
SSH: 5.26 (-0.02), THOR: 40.01 (+0.54), HTWR: 88.18 (-0.09)
Heartware International (HTWR) Shares Cross Above 200 DMA
MarketNewsVideo.com - Thu Jan 22, 3:44PM CST
In trading on Thursday, shares of Heartware International Inc crossed above their 200 day moving average of $82.31, changing hands as high as $82.32 per share. Heartware International Inc shares are currently trading up about 0.7% on the day.
HTWR: 88.18 (-0.09)
HeartWare Announces Preliminary Q4, 2014 Revenue Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 14, 4:55PM CST
HeartWare International, Inc. (HTWR) recently announced preliminary top-line results for fourth quarter and full year 2014.
ABMD: 60.39 (+0.46), INGN: 33.53 (+2.32), HTWR: 88.18 (-0.09), SURG: 4.44 (-0.02)
HeartWare International Announces Preliminary Fourth Quarter 2014 Revenues
PR Newswire - Tue Jan 13, 10:05AM CST
HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that it expects revenues for the fourth quarter of 2014 will be approximately $73 million, bringing expected full-year 2014 revenues to approximately $278 million.
HTWR: 88.18 (-0.09)
HeartWare Begins HVAD® LATERAL Study, A Clinical Trial Of Advanced Heart Failure Patients Implanted Via Less-Invasive Thoracotomy Technique
PR Newswire - Tue Jan 13, 7:30AM CST
HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced the first patient implant in the HVAD® LATERAL Study, a U.S. Investigational Device Exemption (IDE) clinical trial in which the HeartWare® Ventricular Assist System, featuring the HVAD® Pump, is implanted through a less-invasive thoracotomy procedure in patients with end-stage heart failure who are awaiting a heart transplant.
HTWR: 88.18 (-0.09)
HeartWare Presentation At The J.P. Morgan 33rd Annual Healthcare Conference To Be Webcast
PR Newswire - Fri Jan 02, 8:15AM CST
HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the J.P. Morgan 33rd Annual Healthcare Conference at 11:00 a.m. EST (8:00 a.m. PST) on Tuesday, January 13, 2015. The conference is being held January 12-15 at The Westin St. Francis in San Francisco, California.
JPM: 59.67 (+0.10), HTWR: 88.18 (-0.09)
Volcano Acquired by Royal Philips for $1.2B: What Wall Street's Saying
at The Street - Wed Dec 17, 2:20PM CST
Volcano Corp. shares surged more than 50% on Wednesday after Royal Philips agreed to acquire the medical technology company for $1.2 billion.
BSX: 14.98 (+0.24), SPNC: 33.69 (-0.06), ABT: 46.09 (+0.87), PHG: 28.93 (-0.07), MDT: 75.26 (+0.33), TRIV: 10.07 (+0.15), VOLC: 17.98 (+0.03), STJ: 67.48 (+0.65), THOR: 40.01 (+0.54), HTWR: 88.18 (-0.09), ELGX: 14.51 (+0.21), ATRC: 18.86 (+0.04), NVDQ: 15.12 (+0.51)
HeartWare Presentation At The Oppenheimer 25th Annual Healthcare Conference To Be Webcast
PR Newswire - Thu Dec 04, 11:35AM CST
HeartWare International, Inc. (NASDAQ:HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Oppenheimer 25th Annual Healthcare Conference at 10:20 a.m. EST on Wednesday, December 10, 2014. The conference is being held December 10-11, 2014 at the Crowne Plaza Hotel in New York City.
HTWR: 88.18 (-0.09)
Thoratec: At The Heart Of A Health-Related Investment Strategy
Robert Honeywill - at Seeking Alpha - Sun Nov 30, 3:48AM CST
About the headline It is my contention, for Western economies, we will enjoy far lower growth in the future than we have enjoyed over the last several decades. For investors, it is not an optimal strategy to adopt a "rising tide lifts all boats"...
SSH: 5.26 (-0.02), THOR: 40.01 (+0.54), HTWR: 88.18 (-0.09)
HeartWare Presentation At The Canaccord Genuity 2014 Medical Technology & Diagnostics Forum To Be Webcast
PR Newswire - Thu Nov 13, 11:11AM CST
HeartWare International, Inc. (NASDAQ:HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Canaccord Genuity 2014 Medical Technology & Diagnostics Forum at 10:00 a.m. EST on Thursday, November 20, 2014. The one-day conference is being held at the Westin Grand Central, New York.
HTWR: 88.18 (-0.09)
Update: Heartware International Q3 2014 Earnings
Andy Batts - at Seeking Alpha - Sat Nov 08, 1:38PM CST
HTWR: 88.18 (-0.09)
HeartWare Presentation At The Credit Suisse 2014 Healthcare Conference To Be Webcast
PR Newswire - Fri Nov 07, 8:00AM CST
HeartWare International, Inc. (NASDAQ:HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Credit Suisse 2014 Healthcare Conference at 2:00 p.m. MST (4:00 pm EST) on Wednesday, November 12, 2014. The conference is being held November 10-13 at the Arizona Biltmore in Phoenix.
HTWR: 88.18 (-0.09)
Heartware International (HTWR) Downgraded From Hold to Sell
at The Street - Mon Nov 03, 8:38AM CST
Heartware International (HTWR) has been downgraded by TheStreet Ratings from Hold to Sell with a ratings score of D+.
HTWR: 88.18 (-0.09)
